Trial Profile

A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Obinutuzumab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms GIBB
Sponsors Genentech

Most Recent Events

01 Apr 2021 Final results (Data cut off date- 3 June 2019) of the GIBB study, published in the Leukemia and Lymphoma
06 Nov 2019 Results from the GIBB study presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
06 Nov 2019 Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine released at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com